title: [Adverse reactions of atazanavir, fosamprenavir and tipranavir in "real life"].
abstract: OBJECTIVE
  To precise adverse effects of atazanavir, fosamprenavir and tipranavir "in real life".
  
  
  METHODS
  Descriptive study of 3 protease inhibitor adverse effects stored in the French Bank of Pharmacovigilance.
  
  
  RESULTS
  Nineteen adverse effects having at least possible links with antiretroviral drugs studied were reported. It was essentially hepatobiliary (atazanavir: 29/59, tipranavir: 4/6) and skin (fosamprenavir: 10/20) adverse reactions. These reactions, relatively "serious" (35.1%) led to the interruption of the person (or persons) medication (s) suspected (s) in 69 folds (82.1%) and evolved to healing without sequelae in 68 folds (81%).
  
  
  CONCLUSIONS
  The drug side effects were for the most expected. However, their frequency and their seriously underline the interest of a post-AMM monitoring to reassess the drugs risk-benefit report.
authors.affiliation: Centre Hospitalier Universitaire de Cocody (Abidjan), Service de Pharmacologie Clinique, Abidjan, Côte d'Ivoire. ebalayssac@yahoo.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Balayssac
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Autret-Leca
authors.forename: Annie-Pierre
authors.initials: AP
authors.lastname: Jonville-Béra
authors.forename: Henri
authors.initials: H
authors.lastname: Diè-Kacou
authors.forename: Frédérique
authors.initials: F
authors.lastname: Beau-Salinas
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D000069446:Atazanavir Sulfate; D002219:Carbamates / Q000009:adverse effects*; D005602:France; D005663:Furans; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008107:Liver Diseases / Q000209:etiology / Q000473:pathology; D009842:Oligopeptides / Q000009:adverse effects*; D010755:Organophosphates / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011753:Pyrones / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D010755:Organophosphates; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D000069446:Atazanavir Sulfate; C426859:fosamprenavir; C107201:tipranavir